Related Experiment Video
Updated: Dec 27, 2025
Quail Chorioallantoic Membrane - A Tool for Photodynamic Diagnosis and Therapy
Published on: April 28, 2022
Camrelizumab (SHR-1210) leading to reactive capillary hemangioma in the gingiva: A case report
1Department of Periodontology, School and Hospital of Stomatology, Shandong University, Shandong Key Laboratory of Oral Tissue Regeneration, Shandong Engineering Laboratory for Dental Materials and Oral Tissue Regeneration, Jinan 250012, Shandong Province, China.
Background:
Oncologic immunotherapy is attracting attention as an effective strategy for cancer treatment. Currently, there are two kinds of inhibitors: Anti-PD-1 antibodies and anti-PD-L1 antibodies. These inhibitors have shown significant implications in improving the outcomes of certain cancer types in recent years. However, along with its effectiveness, adverse events cannot be ignored. As an anti-PD-1 antibody, camrelizumab (SHR-1210) has some side effects in tumor immunotherapy. The most common adverse event is reactive capillary hemangioma. While it is widely reported to occur in the skin, gingival reactive capillary hemangioma is rarely reported.
Case Summary:
A 54-year-old man complained of gingival overgrowth on the anterior aspect of the maxilla and mandible for more than 6 mo. He had been placed on SHR-1210 for lung cancer for 7 mo. A gingival mass extending from canine to canine was noted on the lingual surfaces of the mandible. Gingival enlargement was noted in the front teeth. A clinical diagnosis of gingival reactive capillary hemangioma and chronic periodontitis was made. The treatment involved a complex local treatment (repeated local applications of an antibiotic paste, scaling and root planning, and surgery). The excised tissue was sent for histopathological examination, which confirmed the diagnosis of capillary hemangioma. After the operation, most of the gingival enlargement was reduced. At the 2-mo follow-up, it was noted that the gingival overgrowth was immediately reduced after the replacement of the anti-PD-1 agent with an anti-PD-L1 agent.
Conclusion:
As the prescription for SHR-1210 has increased considerably in recent years, the occurrence of its possible side effects, including gingival reactive capillary hemangioma, has increased. It is recommended that regular oral examinations be performed before and during the treatment of tumors with SHR-1210.
Insights
Camrelizumab (SHR-1210), an anti-PD-1 antibody, can cause rare gingival reactive capillary hemangioma. Early oral exams and monitoring are recommended during cancer immunotherapy treatment.
Area of Science:
- Oncology
- Immunotherapy
- Dermatology
Background:
- Oncologic immunotherapy utilizes anti-PD-1 and anti-PD-L1 antibodies to treat cancer.
- Camrelizumab (SHR-1210) is an anti-PD-1 antibody with known side effects, including reactive capillary hemangioma.
- Gingival reactive capillary hemangioma is a rare adverse event associated with camrelizumab treatment.
Observation:
- A 54-year-old male patient developed gingival overgrowth during camrelizumab therapy for lung cancer.
- Clinical diagnosis revealed gingival reactive capillary hemangioma and chronic periodontitis.
- Surgical excision and local treatment reduced the gingival enlargement.
Findings:
- Histopathological examination confirmed capillary hemangioma.
- Gingival overgrowth significantly reduced after switching from camrelizumab (anti-PD-1) to an anti-PD-L1 agent.
- Increased use of SHR-1210 correlates with a rise in associated side effects like gingival hemangioma.
Implications:
- Regular oral examinations are crucial before and during treatment with camrelizumab.
- Awareness of rare side effects like gingival reactive capillary hemangioma is important for oncologists and dentists.
- Management may involve switching immunotherapy agents to mitigate adverse events.
